Lyell Wealth Management LP reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,220 shares of the life sciences company’s stock after selling 177 shares during the period. Lyell Wealth Management LP’s holdings in Illumina were worth $3,751,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Kaizen Advisory LLC raised its position in Illumina by 161.0% during the second quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock valued at $103,000 after purchasing an additional 227 shares in the last quarter. Moneta Group Investment Advisors LLC raised its position in Illumina by 2,670.0% during the second quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock valued at $107,000 after purchasing an additional 9,345 shares in the last quarter. Sun Life Financial INC raised its position in Illumina by 152.5% during the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock valued at $111,000 after purchasing an additional 241 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its position in Illumina by 3,192.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock valued at $120,000 after purchasing an additional 415 shares in the last quarter. Finally, Hall Laurie J Trustee raised its position in Illumina by 189.5% during the second quarter. Hall Laurie J Trustee now owns 550 shares of the life sciences company’s stock valued at $154,000 after purchasing an additional 360 shares in the last quarter. Institutional investors and hedge funds own 89.87% of the company’s stock.
Several research analysts have recently issued reports on ILMN shares. Morgan Stanley upped their price target on shares of Illumina from $195.00 to $210.00 and gave the stock an “underweight” rating in a report on Friday, July 13th. BidaskClub downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 4th. Cowen upped their price target on shares of Illumina from $315.00 to $400.00 and gave the stock a “positive” rating in a report on Thursday, September 6th. UBS Group started coverage on shares of Illumina in a report on Tuesday, October 9th. They set a “neutral” rating and a $340.00 price target for the company. Finally, ValuEngine downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $330.94.
NASDAQ ILMN opened at $310.14 on Wednesday. The firm has a market capitalization of $43.38 billion, a P/E ratio of 77.54, a P/E/G ratio of 2.17 and a beta of 0.97. Illumina, Inc. has a twelve month low of $203.39 and a twelve month high of $372.61. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.46 and a quick ratio of 2.24.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.26 by $0.26. The business had revenue of $853.00 million during the quarter, compared to the consensus estimate of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. Illumina’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.11 earnings per share. On average, sell-side analysts anticipate that Illumina, Inc. will post 5.75 EPS for the current fiscal year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Recommended Story: Intrinsic Value
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.